Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.

Awad AS, Gao T, Gvritishvili A, You H, Liu Y, Cooper TK, Reeves WB, Tombran-Tink J.

Am J Physiol Renal Physiol. 2013 Sep 15;305(6):F891-900. doi: 10.1152/ajprenal.00149.2013.

2.

Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury.

Awad AS, You H, Gao T, Gvritishvili A, Cooper TK, Tombran-Tink J.

PLoS One. 2015 Jul 24;10(7):e0133777. doi: 10.1371/journal.pone.0133777.

3.

Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.

Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S.

Pharmacol Res. 2011 Mar;63(3):241-8. doi: 10.1016/j.phrs.2010.11.008.

PMID:
21115116
4.

Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy.

Wang JJ, Zhang SX, Mott R, Chen Y, Knapp RR, Cao W, Ma JX.

Am J Physiol Renal Physiol. 2008 May;294(5):F1166-73. doi: 10.1152/ajprenal.00375.2007.

5.

Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities.

Wang JJ, Zhang SX, Mott R, Knapp RR, Cao W, Lau K, Ma JX.

Diabetes. 2006 Jun;55(6):1678-85.

6.

Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.

Fujimura T, Yamagishi S, Ueda S, Fukami K, Shibata R, Matsumoto Y, Kaida Y, Hayashida A, Koike K, Matsui T, Nakamura K, Okuda S.

Nephrol Dial Transplant. 2009 May;24(5):1397-406. doi: 10.1093/ndt/gfn659.

PMID:
19042927
7.

Protective Role of PEDF-Derived Synthetic Peptide Against Experimental Diabetic Nephropathy.

Ishibashi Y, Matsui T, Taira J, Higashimoto Y, Yamagishi S.

Horm Metab Res. 2016 Sep;48(9):613-9. doi: 10.1055/s-0042-108448.

PMID:
27214310
8.

Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy.

Wang JJ, Zhang SX, Lu K, Chen Y, Mott R, Sato S, Ma JX.

Diabetes. 2005 Jan;54(1):243-50.

9.

Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats.

Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Fernandez M.

Gut. 2015 Apr;64(4):657-66. doi: 10.1136/gutjnl-2014-307138.

PMID:
24848263
11.

Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications.

Yamagishi S, Matsui T, Nakamura K, Ueda S, Noda Y, Imaizumi T.

Curr Drug Targets. 2008 Nov;9(11):1025-9. Review.

PMID:
18991613
12.

Pigment epithelium-derived factor (PEDF) peptide eye drops reduce inflammation, cell death and vascular leakage in diabetic retinopathy in Ins2(Akita) mice.

Liu Y, Leo LF, McGregor C, Grivitishvili A, Barnstable CJ, Tombran-Tink J.

Mol Med. 2012 Dec 20;18:1387-401. doi: 10.2119/molmed.2012.00008.

13.

Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy.

Yoshida Y, Yamagishi S, Matsui T, Jinnouchi Y, Fukami K, Imaizumi T, Yamakawa R.

Diabetes Metab Res Rev. 2009 Oct;25(7):678-86. doi: 10.1002/dmrr.1007.

PMID:
19685553
14.

Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.

Awad AS, You H, Gao T, Cooper TK, Nedospasov SA, Vacher J, Wilkinson PF, Farrell FX, Brian Reeves W.

Kidney Int. 2015 Oct;88(4):722-33. doi: 10.1038/ki.2015.162.

15.

Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy.

Chen H, Zheng Z, Li R, Lu J, Bao Y, Ying X, Zeng R, Jia W.

Am J Nephrol. 2010;32(1):47-56. doi: 10.1159/000314326. Erratum in: Am J Nephrol. 2010;32(3):286.

16.

Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.

Ichinose K, Maeshima Y, Yamamoto Y, Kitayama H, Takazawa Y, Hirokoshi K, Sugiyama H, Yamasaki Y, Eguchi K, Makino H.

Diabetes. 2005 Oct;54(10):2891-903. Erratum in: Diabetes. 2006 Sep;55(9):2665.

17.

Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes.

Hui E, Yeung CY, Lee PC, Woo YC, Fong CH, Chow WS, Xu A, Lam KS.

J Clin Endocrinol Metab. 2014 Nov;99(11):E2169-77. doi: 10.1210/jc.2014-2235.

18.

Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice.

Xiao T, Guan X, Nie L, Wang S, Sun L, He T, Huang Y, Zhang J, Yang K, Wang J, Zhao J.

Mol Cell Biochem. 2014 Sep;394(1-2):145-54. doi: 10.1007/s11010-014-2090-7.

PMID:
24850187
19.

Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential.

Barnstable CJ, Tombran-Tink J.

Prog Retin Eye Res. 2004 Sep;23(5):561-77. Review.

PMID:
15302351
20.

The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential.

Becerra SP, Notario V.

Nat Rev Cancer. 2013 Apr;13(4):258-71. doi: 10.1038/nrc3484. Review.

Supplemental Content

Support Center